FOXO is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO’s epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. FOXO seeks to modernize the life insurance industry by simplifying the consumer underwriting journey with saliva-based biomarkers and enhancing life insurance’s consumer value proposition with the FOXO Longevity Report™. For more information about FOXO, visit www.foxotechnologies.com. For more information about FOXO LIFE, visit www.foxolife.com. For investor information and updates, visit https://foxotechnologies.com/investors.

Company profile
Ticker
FOXO, FOXO-WT
Exchange
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Delwinds Insurance Acquisition Corp.
SEC CIK
Corporate docs
IRS number
851050265
FOXO stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
20 Mar 23
8-K
Other Events
20 Mar 23
424B3
Prospectus supplement
10 Mar 23
SC TO-C
Information about tender offer
10 Mar 23
8-K
Other Events
10 Mar 23
424B4
Prospectus supplement with pricing info
15 Feb 23
EFFECT
Notice of effectiveness
15 Feb 23
CORRESP
Correspondence with SEC
13 Feb 23
S-1/A
IPO registration (amended)
10 Feb 23
CORRESP
Correspondence with SEC
10 Feb 23
Latest ownership filings
SC 13G/A
GLAZER CAPITAL, LLC
14 Feb 23
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
9 Feb 23
3
Taylor Fay
3 Feb 23
SC 13D/A
DIAC Sponsor LLC
26 Sep 22
SC 13D
Sabes Jon
26 Sep 22
4
Change in insider ownership
22 Sep 22
4
Andrew J. Poole
22 Sep 22
3
Andrew J. Poole
22 Sep 22
4
Tyler Danielson
16 Sep 22
4
Robert Potashnick
16 Sep 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.45 mm | 10.45 mm | 10.45 mm | 10.45 mm | 10.45 mm | 10.45 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.94 mm | 1.14 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 16.79 mm | 6.52 mm | n/a | n/a |
Cash remaining | n/a | n/a | -6.34 mm | 3.93 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | -2.2 | 3.4 | n/a | n/a |
Institutional ownership, Q4 2022
13F holders | Current |
---|---|
Total holders | 38 |
Opened positions | 5 |
Closed positions | 10 |
Increased positions | 5 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 289.52 mm |
Total shares | 324.25 mm |
Total puts | 0.00 |
Total calls | 134.38 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BlueCrest Capital Management | 319.18 mm | $85.86 mm |
Sabes Jon | 1.16 mm | $0.00 |
Shaolin Capital Management | 750.99 k | $20.00 k |
Cinctive Capital Management | 350.00 k | $9.42 mm |
Radcliffe Capital Management | 250.00 k | $94.75 mm |
HGC Investment Management | 250.00 k | $25.00 k |
Mizuho Securities Usa | 240.00 k | $2.40 mm |
Adage Capital Partners GP, L.L.C. | 236.64 k | $6.37 mm |
Polar Asset Management Partners | 171.50 k | $4.03 mm |
LMR Partners | 150.00 k | $56.85 mm |
News
12 Information Technology Stocks Moving In Friday's After-Market Session
17 Mar 23
12 Information Technology Stocks Moving In Wednesday's After-Market Session
15 Mar 23
12 Information Technology Stocks Moving In Tuesday's After-Market Session
14 Mar 23
12 Information Technology Stocks Moving In Friday's After-Market Session
10 Mar 23
12 Information Technology Stocks Moving In Tuesday's Intraday Session
7 Mar 23